Skip to content

Released Mar 4, 2020, after the close

10-K filed Mar 4, 2020, 64 days after period end · 0001564590-20-008696

Q4 2019 · 10-K
Revenue$4.77M+27.6% vs Q4 2018+12.7% vs Q3 2019
Net Income-$27.08MN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.99N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$28,684,000N/M
Operating Cash Flowderived-$20,528,000N/M
Free Cash Flowderived-$20,543,000N/M
Margins · derived
Operating margin-601.7%+103.0 pt vs Q4 2018
Net margin-568.2%+132.3 pt vs Q4 2018

What the release said

The release

Same quarter

MetricQ4 2019Q4 2018Q4 2017Q4 2016
Revenue$4.77M$3.74M$3.32M—
Net Income-$27.08M-$26.16M-$3.01M-$11.55M
EPS Diluted-$0.99-$1.03-$160.00-$0.67

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR